Gastrointestinal Microbiome, Liver Disease Chronic, Sarcopenia
Conditions
Brief summary
The purpose of this study was to confirm the presence of specific gut microbiota observed in patients with sarcopenia among patients who agreed to analyze gut microbiota through stool among multi-center chronic liver disease cohort patients.
Detailed description
The effect of gut microbiota on liver disease is also well known and many studies are ongoing. A recently published study summarized the differences in the composition of gut microbiota in non-alcoholic fatty liver, steatohepatitis, and cirrhosis, and reported that metabolites from the changed gut microbiota may be a factor influencing non-alcoholic fatty liver disease (NAFLD) progression. These changes in gut microbiota composition have been reported to affect clinical outcomes in patients by causing an increase in endotoxin, a change in bile acid metabolism, and a decrease in short chain fatty acid. In particular, the reduction of short chain fatty acid is known to be associated with the occurrence of sarcopenia. Sarcopenia, which is common in patients with cirrhosis, which is a representative chronic liver disease, is well known as a poor prognostic factor for patients. Therefore, this study aims to analyze the distribution of gut microbiota observed in patients with sarcopenia through the gut microbiota investigated in the chronic liver disease cohort patient group and the characteristics of the distribution of gut microbiota for each disease corresponding to chronic liver disease.
Interventions
DIAGNOSTIC_TESTSarcopenia_CT
measurement of skeletal muscle through abdominal computed tomography
Sponsors
Dongtan Sacred Heart Hospital
Hallym University Medical Center
Hangang Sacred Heart Hospital
Kangdong Sacred Heart Hospital
Yonsei University
Chuncheon Sacred Heart Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
24 Years to 82 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Patients who have chronic liver disease (chronic liver disease cohort): alcohol liver disease, non-alcoholic liver disease, liver cirrhosis 2. Patients who consented to a study confirming the gut microbiota 3. Patients with abdominal computed tomography scan taken one month before or after submitting stool for gut microbiota analysis
Exclusion criteria
* Patients whose height and weight records are missing from the chart review
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fecal gut microbiota between sarcopenia group and non-sarcopenia group | 2 years | Compare the species and proportions of the gut microbiota between sarcopenia group and non-sarcopenia group |
Countries
South Korea
Outcome results
None listed